Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Imfinzi (Durvalumab)
Table Of Contents
Durvalumab is an immunotherapy treatment for bladder cancer and lung cancer. AstraZeneca manufactures the drug and markets it under the brand name Imfinzi. Durvalumab helps the immune system fight cancer, and clinical trials are testing it on a variety of diseases, including mesothelioma.
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: September 10, 2024
"Most helpful, steered us in the right direction for treatment. Great source of information and support, the Center followed through on every one of our requests...." see more
Elaine C.
Mesothelioma Patient
"Because of their guidance, I was able to navigate getting my mother into MD Anderson when her case got put aside by mistake in all the COVID-19 craziness. Vanes...." see more
Deanna B.
Daughter of a Mesothelioma Patient
"Hearing the news about my mother's diagnosis was heartbreaking. I felt lost, I didn't know how I could help or where to seek the best medical care. I started re...." see more
Danielle W.
Daughter of a Mesothelioma Patient
"My son Carlos was diagnosed with this terrible and unknown disease a few months ago. Thank God we found The Mesothelioma Center along the way, and Vanessa Blanc...." see more
Martha M.
Mother of a Mesothelioma Patient
"Extremely communicative and helped my dad get an appointment with one of the top centers in Philadelphia. I'm so grateful for this center. They assisted with in...." see more
Sunni H.
Loved One of a Mesothelioma Patient
"Danielle DiPietro was an invaluable resource for me. Her suggestions and recommendations guided us towards stellar practitioners in our area. Without her advoca...." see more
Deborah C.
Spouse of a Mesothelioma Patient
"I was very grateful and appreciative of Dr. Smart from The Mesothelioma Center. She was very helpful to my husband and me. She educated and walked us through th...." see more
Kimberlin C.
Spouse of a Mesothelioma Patient
"In January of 2016, my husband was diagnosed with peritoneal mesothelioma. Our first reaction was: what is this and what can we do? He was diagnosed by an oncol...." see more
Gloria R.
Spouse of a Mesothelioma Patient
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: September 10, 2024
What Is Imfinzi (Durvalumab)?
The U.S. Food and Drug Administration approved immunotherapy drug Imfinzi (Durvalumab) in May 2017 to treat late-stage bladder cancer. It’s approved specifically to treat urothelial carcinomas when they can’t be removed with surgery and have recurred after chemotherapy.
Clinical trials have tested the drug on patients with a variety of cancers including lung cancer, melanoma, pancreatic cancer, gastric cancer, head and neck cancer, esophageal cancer, lymphoma, myelodysplastic syndrome and solid tumors. The best results in these trials occurred in lung cancer patients.
| Durvalumab Information | |
|---|---|
| Name | Durvalumab |
| Alternate Names | Imfinzi, MEDI4736 |
| Manufacturer | AstraZeneca |
| Dosage | 10 mg/kg |
| Administration Route | IV |
| Active Ingredient | Durvalumab |
| Drug Class | Checkpoint inhibitor, monoclonal antibody |
| Medical Code | C9492 |
| Interacting Drug | Vaccines, vitamin E, zinc, cat’s claw, echinacea |
| Medical Studies | A phase 2 study of durvalumab in combination with tremelimumab in malignant pleural mesothelioma |
| FDA Warning | Pneumonitis, liver disease, colitis, kidney inflammation, endocrine gland disease, infection, infusion reactions, fetal harm |
A phase III clinical trial of durvalumab for stage 3 lung cancer patients reported the drug stopped tumor growth for an average of 11 months. Some patients showed no new tumor growth after chemotherapy and radiation therapy.
In July 2017, the FDA designated durvalumab as a breakthrough therapy, expediting the drug’s development and review. In February 2018, the FDA approved durvalumab for lung cancer treatment.
How Does Durvalumab Work?
Durvalumab is a checkpoint inhibitor that blocks PD-L1. It’s in the same class as the immunotherapy drug Keytruda. Checkpoint inhibitors boost the body’s natural defenses against cancer cells.
PD-L1 is a protein on the surface of cancer cells that works like a mask to hide cancer from the immune system. Durvalumab blocks PD-L1 and removes the mask so the immune system can identify and attack cancer cells. About 50% of mesothelioma cells carry high amounts of PD-L1 to hide from the immune system. Doctors often test patients for this protein to check if durvalumab will be effective in their treatment.
Our research shows doctors often combine durvalumab with traditional mesothelioma treatments such as surgery and chemotherapy with platinum-based drugs. Immunotherapy drugs are typically effective after chemotherapy stops working or when cancer returns.
Side Effects of Imfinzi (Durvalumab) for Mesothelioma
Durvalumab stimulates the immune system and may cause it to attack healthy organs and tissues. Side effects range from mild to severe.
Mild Side Effects of Imfinzi
- Abdominal pain
- Bone and muscle pain
- Constipation
- Diarrhea
- Fatigue
- Fever
- Loss of appetite
- Nausea
- Swelling in arms or legs
- Urinary tract infection
Other mild side effects include reduced sodium in the blood and low white blood cell count. Doctors can prescribe medication to treat most mild to moderate side effects of durvalumab.
Serious Side Effects of Imfinzi (Durvalumab)
Signs of severe infusion reactions include chills or shaking, fever, dizziness, wheezing, shortness of breath or lightheadedness. Flushing, itching or rash, facial swelling and back or neck pain can also occur.
Serious Imfinzi Side Effects
- Damage to hormone glands (thyroid, adrenals, pituitary and pancreas)
- Difficulty breathing
- Infections
- Inflammation in the lungs
- Inflammation of the colon lining
- Infusion-related reactions
- Kidney problems
- Liver disease
- Skin problems (rash, itching and blisters)
Talk to your doctor immediately if you notice any mild or severe side effects. Seek medical treatment quickly to keep side effects under control.
Can Imfinzi Treat Mesothelioma?
Promising results in lung cancer patients led to clinical trials testing durvalumab in patients with mesothelioma. A trial launched in February 2022 is recruiting 480 patients (320 durvalumab and chemotherapy, 160 chemotherapy) over 27 months and following them for another 24 months.
Dana-Farber Cancer Institute in Boston also conducted a phase II clinical trial in April 2017 that tested testing durvalumab and tremelimumab among patients who don’t qualify for mesothelioma surgery. Mesothelioma survivor and Navy veteran Jim McWhorter participated in Dana-Farber’s clinical trial, and he initially responded well. His cancer stopped growing for several months. Then, a CT scan showed the tumor was growing again, and McWhorter had to leave the trial in search of other options.
In 2015, an Italian phase II trial began testing durvalumab and tremelimumab on mesothelioma patients who didn’t qualify for surgery. Around 62% of participants responded to durvalumab and tremelimumab, but the immunotherapy study failed to improve survival. Doctors leading the study said more research is necessary.
Jim McWhorter
Verified Asbestos.com Survivor
Navy Veteran Pursues Mesothelioma Immunotherapy Trials
Jim was able to get into a clinical trial at Dana-Farber Cancer Institute in Boston, testing a combination of the immunotherapy drugs durvalumab and tremelimumab. For the first few months, the results were extremely positive. The cancer had stabilized.
Are All Mesothelioma Patients Eligible for Imfinzi (Durvalumab)?
Mesothelioma patients who have a high rate of PD-L1 tumor mutation are eligible for durvalumab. Patients must also have had cancer return after trying prior treatment. About 20% to 40% of pleural mesothelioma patients express high levels of PD-L1. This protein is also more common in non-epithelial mesothelioma tumors.
The FDA is reviewing the combination of durvalumab with chemotherapy for patients with a new mesothelioma diagnosis. Durvalumab is currently available as a second-line treatment for late-stage mesothelioma and through clinical trials with varying eligibility requirements. Surgery, chemotherapy and radiation therapy in a multimodal treatment plan is still the standard of care for the first-line treatment of early-stage mesothelioma.
This Page Contains 13 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- Forde, P. et al. (2022, February 1). DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial. Retrieved from https://linkinghub.elsevier.com/retrieve/pii/S0360301621031527
- Hirschler, B., & Grover, D. (2017, May 1). AtraZeneca immunotherapy wins first approval in bladder cancer. Retrieved from https://www.reuters.com/article/us-astrazeneca-fda/astrazeneca-immunotherapy-wins-first-approval-in-bladder-cancer-idUSKBN17X22Y
- National Cancer Institute. (2017, August 10). Durvalumab. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab
- Medscape. (n.d.). Durvalumab (Rx). Retrieved from https://reference.medscape.com/drug/imfinzi-durvalumab-1000145
- Medline Plus. (2017, July 15). Durvalumab injection. Retrieved from https://medlineplus.gov/druginfo/meds/a617030.html
- AstraZeneca. (2017, September 8).AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html
- AstraZeneca. (2017, October 17). US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html
- Calabro, L. et al. (2017). Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study. Retrieved from http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8558
- FDA. (n.d.). Highlights of prescribing information: Imfinzi. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf#page=19
- ClinicalTrials.gov. (2018, January 19). A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma. Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT03075527
- ClinicalTrials.gov. (2015, October 27). A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1). Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT02588131
- AstraZeneca.com. (2016, February 29). AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma. Retrieved from https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html
- Antonia, S., Goldberg, S., et al. (2016, February 5). Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicenter, phase I b study. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/26858122
Get Your Free Mesothelioma Treatment Guide
Mesothelioma & Immunotherapy Webinar
Immunotherapy & Mesothelioma Clinical Trials
